Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tanshinone IIA is a lipophilic diterpene quinone and the main active component extracted from the roots of Salvia miltiorrhiza (Danshen), a traditional Chinese medicinal herb. It is widely used in China and neighboring countries for cardiovascular diseases, diabetes, apoplexy (stroke), arthritis, sepsis, and other conditions. Pharmacologically, it exhibits anti-inflammatory, antioxidant, immunomodulatory, anti-tumor/anticancer effects (including inhibition of cell proliferation and induction of apoptosis in various cancer cell lines), as well as protective effects on vascular endothelial cells and smooth muscle cells. Mechanistically, it modulates multiple signaling pathways such as PI3K/Akt/mTOR inhibition, p53 activation, RAF/MEK pathway activation in cancer models; suppresses NF-kappaB activity; downregulates inflammatory mediators like CCL2; regulates immune cell function; inhibits oxidative stress; reduces vascular smooth muscle proliferation/migration; stabilizes atherosclerotic plaques by inhibiting apoptosis/inflammation of VSMCs; inhibits foam cell formation by macrophages. It has also shown renoprotective effects via modulation of fibrotic/inflammatory pathways[1][3][5][7][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tanshinone IIA.